v3.21.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Revenue
Operating expenses:        
Commercial operations 1,973 460 3,360 845
General and administrative 6,739 2,421 10,113 4,721
Research and development 4,258 2,133 7,573 4,702
Total operating expenses 12,970 5,014 21,046 10,268
Loss from operations (12,970) (5,014) (21,046) (10,268)
Other income (expense):        
Interest expense (52)
Change in fair value - Senior Secured Convertible Notes and Senior Convertible Note 2,120 1,682 (5,888)
Offering costs - Senior Secured Convertible Note and Senior Convertible Note (200) (610)
Debt extinguishments loss - Senior Secured Convertible Notes (2,750) (3,715) (3,937)
Debt forgiveness 300 300
Other income (expense), net 300 (830) (1,733) (10,487)
Loss before provision for income tax (12,670) (5,844) (22,779) (20,755)
Provision for income taxes
Net loss before noncontrolling interests (12,670) (5,844) (22,779) (20,755)
Net loss attributable to the noncontrolling interests 1,199 266 1,877 702
Net loss attributable to PAVmed Inc. (11,471) (5,578) (20,902) (20,053)
Less: Series B Convertible Preferred Stock dividends earned (74) (71) (149) (141)
Net loss attributable to PAVmed Inc. common stockholders $ (11,545) $ (5,649) $ (21,051) $ (20,194)
Per share information:        
Net loss per share attributable to PAVmed Inc. - basic and diluted $ (0.14) $ (0.12) $ (0.27) $ (0.45)
Net loss per share attributable to PAVmed Inc. common stockholders – basic and diluted $ (0.14) $ (0.13) $ (0.27) $ (0.46)
Weighted average common shares outstanding, basic and diluted 82,235,397 44,780,538 78,117,637 44,140,126

Source